/PRNewswire/ XNK Therapeutics AB ("XNK") today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial ACP-001 with its.
STOCKHOLM, June 10, 2022 /PRNewswire/ XNK Therapeutics AB ("XNK") today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial ACP-001 with its leading candidate
/PRNewswire/ XNK Therapeutics AB ("XNK") today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial study ACP-001 with its.
XNK Therapeutics Reports First Patient Included in Phase II Study in Multiple Myeloma prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.